Devi Nampiaparampil
Interventional Pain Medicine · New York, NYNPI 1205982501
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,940 of the $18,297 with a category attached, or 70.7%. AbbVie accounts for 75.2% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2021 at $7,999 and has fallen 99.5% since, to $40 in 2025.
Across 98 payments — averaging $186.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$14K
- Biohaven Pharmaceuticals, Inc.$1K
- Bioventus LLC$1K
- Amgen$436
- Neuronetics, Inc.$410
- Teva Pharmaceuticals USA, Inc.$281
- plus $1K from 14 others
What the payments were for
- Consulting fees$1,2007%
- Speaking & faculty fees$12,94071%
- Travel & lodging$8665%
- Food & beverage$3,22018%
- Education$710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 49 | $13,763 |
| Biohaven Pharmaceuticals, Inc. | 1 | $1,200 |
| Bioventus LLC | 7 | $1,129 |
| Amgen(2 entities) | 14 | $436 |
| Neuronetics, Inc. | 3 | $410 |
| Teva Pharmaceuticals USA, Inc. | 4 | $281 |
| Flowonix Medical Incorporated | 1 | $191 |
| Si-bone, Inc. | 2 | $151 |
| Boston Scientific | 1 | $144 |
| MML US, Inc. | 1 | $131 |
| Abbott | 1 | $121 |
| Curonix LLC | 1 | $98 |
| Stimwave Technologies Incorporated | 1 | $51 |
| Idorsia Pharmaceuticals US Inc | 3 | $49 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Johnson & Johnson | 2 | $33 |
| Fidia Pharma USA Inc. | 2 | $30 |
| Stratus Medical, LLC | 1 | $20 |
| Pfizer | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$13,065
- NURTEC ODT$1,200
- Durolane$1,015
- NEUROSTAR TMS THERAPY SYSTEM$356
- AJOVY$260
- Prometra II$191
- iFuse Implant$136
- ReActiv8$131
- AIMOVIG$125
- Neuromodulation Dspsbls and Accs$121
How this compares
$18,297 in reported general payments places this provider in the 85th percentile of 132 interventional pain medicine providers in New York.
See all interventional pain medicine providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 31 | $1,130 |
| Tramadol Hcl | 12 | $251 |
| Pregabalin | 11 | $68 |
| Topiramate | 15 | $31 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in New York
- Corey HunterNew York$446K
- Neel MehtaNew York$432K
- Kimberly SackheimNew York$102K
- Suelane OuroNew York$68K
- Gerard DegregorisNew York$49K
- Marco PappagalloNew York$36K
- Jason SieffermanNew York$29K
- Barthelemy LiabaudNew York$20K
- Jeffrey DeygooNew York$11K
- Imran PunekarNew York$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.